Rezolute, Inc.
(NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants enrolled so far achieved the study's primary endpoint.
Tumor hyperinsulinism is a rare condition caused by certain islet cell and non-islet cell tumors that trigger hypoglycemia through overactivation of the insulin receptor.
Insulinomas, the most common type of islet cell tumor, cause hypoglycemia by stimulating excessive insulin production. • Rezolute shares are powering higher.
What's fueling RZLT momentum?
